Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 1.00 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.61 |
| ▸ | PDE8A | O60658 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 5/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100084 | 0.91 | PDE7A (0.84) | PDE7APDE7BPDE8ALMNATSHR | |
| SCHEMBL136571 | 0.88 | PDE7A (0.79) | PDE7APDE7BPDE8ATSHRSIGMAR1 | |
| SCHEMBL30837922 | 0.88 | PDE7A (0.79) | PDE7APDE7BPDE8ATSHRSIGMAR1 | |
| SCHEMBL100675 | 0.81 | PDE7A (0.76) | PDE7APDE7BPDE8ALMNATSHR | |
| SCHEMBL30837883 | 0.81 | PDE7A (0.76) | PDE7APDE7BPDE8ALMNATSHR | |
| SCHEMBL10320444 | 0.81 | PDE7A (0.76) | PDE7APDE7BPDE8ALMNATSHR | |
| SCHEMBL99714 | 0.80 | PDE7A (0.76) | PDE7APDE7BPDE8ALMNATSHR | |
| SCHEMBL30837862 | 0.78 | PDE7A (0.73) | PDE7APDE7BPDE8ALMNATSHR | |
| SCHEMBL100713 | 0.78 | PDE7A (0.83) | PDE7APDE7BPDE8ALMNATSHR | |
| SCHEMBL30837831 | 0.78 | PDE7A (0.83) | PDE7APDE7BPDE8ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205593-B1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2016-01-13 | — | — | EP | claimed |
| EP-2416777-B1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI SA (FR) | 2014-11-12 | — | — | EP | claimed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| EP-2411009-B1 | Therapeutic uses of quinazolinedione derivatives | SANOFI SA (FR) | 2013-03-20 | — | — | EP | claimed |
| US-8242126-B2 | Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2012-08-14 | — | — | US | claimed |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-07-19 | — | — | US | claimed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| EP-2205593-B1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2016-01-13 | — | — | EP | disclosed |
| EP-2416777-B1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI SA (FR) | 2014-11-12 | — | — | EP | disclosed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | PPARD, DPP4, NDUFB7 | PDE7A 941/4885PDE7B 1077/4885PDE8A 2165/4885 |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | PDE7A 5/4885PDE7B 14/4885PDE8A 8/4885 |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | FABP3, SLC5A1, SLC5A2 | PDE7A 1769/4885PDE7B 937/4885PDE8A 2886/4885 |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SLC5A2, SLC5A1, PPARD | PDE7A 1520/4885PDE7B 1364/4885PDE8A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.